Physician profile
Guy Kezirian
$11,807,411.41
in general payments reported to CMS, 2019-2025
3 companies · $2.0M in 2025
The $2.0M reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2.2M · 2020: $1.7M · 2021: $1.5M · 2022: $1.5M · 2023: $1.2M · 2024: $1.8M · 2025: $2.0M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $4.9M · Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $4,923,375.00 |
| Food and Beverage | $229.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $11,353,576.41 | 2019-2025 | |
| Alcon Research LLC | $453,750.00 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $85.00 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Kezirian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.